The role of pentraxin 3 as diagnostic value in classification of patients with heart failure

Abstract

Objective: Pentraxin 3 (PTX3) is a new inflammatory marker that is the prototype of the long pentraxin group, while C-reactive protein (CRP) is the short pentraxin group. The aim of the present study was to investigate the clinical significance of plasma PTX3 and CRP levels in heart failure (HF). Materials and methods: The study included 22 male and 37 female patients with HF, and 23 healthy volunteers as the control group. Patients were divided into 4 groups (class I, II, III and IV) according to New York Heart Association functional class. Results: Plasma PTX3 and CRP levels were significantly elevated in HF patients compared to healthy controls. Comparing PTX3 levels in patient groups, statistically significant difference was found between class-I and class-II, class-III and class-Of patients (p = 0.009, p = 0.001, p < 0.001, respectively). There was a positive correlation between PTX3 and CRP levels (r = 0.369, p = 0.004). In receiver-operating characteristic (ROC) curves, area under the curve (AUC) values for PTX3 and CRP were 0.928 (p = 0.001) and 0.834 (p = 0.001), respectively. Conclusions: Plasma PTX3 levels are elevated in HF and might be used as diagnostic value in classification of patients with HF. It is still debated whether inflammation may be just a cause or a consequence of the disease. Therefore further work is needed to better understand in large populations of patients with HF. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.